B+
Bull case
25%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-04-21 · RankAlpha Sentiment Codex
IMUX
ImmunicFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that Immunic now has a meaningfully improved cash position after the February 2026 private placement, removing the most immediate financing pressure, while the late-2026 ENSURE readout offers substantial re-rating potential if efficacy and safety support the RMS thesis [#10-K-2026-02-26].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta 0.0.
What can break
Future capital structure complexity, including warrant-related overhang, could restrain upside even after financing.
Momentum
80
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.80 · Bull $1.80 · Bear $0.35Analysis 2026-04-21; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $43.05
Why
Momentum80 · Δ7d +2.4
Value41 · Δ7d 0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • Future capital structure complexity, including warrant-related overhang, could restrain upside even after financing.
- • Late-2026 ENSURE readout is the dominant binary catalyst; failure would likely overwhelm balance-sheet improvement.
- • The bear case is that this is still a low-coverage, small-cap biotech with a negative deterministic prior, a fresh reverse-split overhang on April 27, 2026, and a thesis that remains highly dependent on a single late-stage binary readout; if ENSURE disappoints, downside could be severe [#8-K-2026-04-14] [#10-K-2026-02-26].
Catalyst clock
2026-04-27
April 27 reverse split is the immediate trading overhang
Lead driver: Value · See fundamentals
Momentum
80
9% active weight
Current posture
7d trendImproving
Δ7d
+2.4
Δ21d
-5.8
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 80.0 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-21. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.80
Analysis reference price unavailable
Analysis 2026-04-21 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.35
Analysis reference price unavailable
Analysis 2026-04-21 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$218.72M
Beta
1.57
Shares Out
13.64M
P/E (TTM) · Derived
-2.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-4.05
Rev YoY
-
EPS YoY
-60.5%
Gross Margin
-
Op Margin
-
Net Debt
-$14.91M
Current Ratio
5.05
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data